<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T04:40:49Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10459.1/67781" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10459.1/67781</identifier><datestamp>2024-12-05T22:27:29Z</datestamp><setSpec>com_2072_3622</setSpec><setSpec>col_2072_479130</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Glial activation and central synapse loss, but not motoneuron degeneration, are prevented by the sigma-1 receptor agonist PRE-084 in the Smn2B/- mouse model of spinal muscular atrophy</dc:title>
   <dc:creator>Cerveró Cebrià, Clàudia</dc:creator>
   <dc:creator>Blasco Carmona, Alba</dc:creator>
   <dc:creator>Tarabal Mostazo, Olga</dc:creator>
   <dc:creator>Casanovas i Llorens, Anna</dc:creator>
   <dc:creator>Piedrafita Llorens, Lídia</dc:creator>
   <dc:creator>Navarro, Xavier</dc:creator>
   <dc:creator>Esquerda Colell, Josep</dc:creator>
   <dc:creator>Calderó i Pardo, Jordi</dc:creator>
   <dc:subject>spinal muscular atrophy</dc:subject>
   <dc:subject>Motoneuron</dc:subject>
   <dc:subject>C-boutons</dc:subject>
   <dc:subject>Microglia</dc:subject>
   <dc:subject>Sigma-1 receptor</dc:subject>
   <dc:subject>Motoneuron synaptic afferents</dc:subject>
   <dc:subject>Smn2B/- mouse</dc:subject>
   <dc:subject>SMNΔ7 mouse</dc:subject>
   <dc:subject>Spinal muscular atrophy</dc:subject>
   <dc:description>Spinal muscular atrophy (SMA) is characterized by the loss of α-motoneurons (MNs) with concomitant muscle denervation. MN excitability and vulnerability to disease are particularly regulated by cholinergic synaptic afferents (C-boutons), in which Sigma-1 receptor (Sig1R) is concentrated. Alterations in Sig1R have been associated with MN degeneration. Here, we investigated whether a chronic treatment with the Sig1R agonist PRE-084 was able to exert beneficial effects on SMA. We used a model of intermediate SMA, the Smn2B/− mouse, in which we performed a detailed characterization of the histopathological changes that occur throughout the disease. We report that Smn2B/− mice exhibited qualitative differences in major alterations found in mouse models of severe SMA: Smn2B/− animals showed more prominent MN degeneration, early motor axon alterations, marked changes in sensory neurons, and later MN deafferentation that correlated with conspicuous reactive gliosis and altered neuroinflammatory M1/M2 microglial balance. PRE-084 attenuated reactive gliosis, mitigated M1/M2 imbalance, and prevented MN deafferentation in Smn2B/− mice. These effects were also observed in a severe SMA model, the SMNΔ7 mouse. However, the prevention of gliosis and MN deafferentation promoted by PRE-084 were not accompanied by any improvements in clinical outcome or other major pathological changes found in SMA mice.</dc:description>
   <dc:description>This work was supported by grants from the Ministerio de Economía y Competitividad co-financed by FEDER (SAF2015-70801).</dc:description>
   <dc:date>2020-01-09T11:03:28Z</dc:date>
   <dc:date>2020-01-09T11:03:28Z</dc:date>
   <dc:date>2018</dc:date>
   <dc:date>2020-01-09T11:03:31Z</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
   <dc:identifier>https://doi.org/10.1093/jnen/nly033</dc:identifier>
   <dc:identifier>0022-3069</dc:identifier>
   <dc:identifier>http://hdl.handle.net/10459.1/67781</dc:identifier>
   <dc:identifier>http://hdl.handle.net/10459.1/67781</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>info:eu-repo/grantAgreement/MINECO//SAF2015-70801-R/ES/LOS AFERENTES SINAPTICOS DE TIPO C EN LAS MOTONEURONAS: IMPLICACIONES EN LA FISIOPATOLOGIA Y TERAPIA DE LA ESCLEROSIS LATERAL AMIOTROFICA Y DE LA ATROFIA MUSCULAR ESPINAL/</dc:relation>
   <dc:relation>Versió postprint del document publicat a: https://doi.org/10.1093/jnen/nly033</dc:relation>
   <dc:relation>Journal of Neuropathology and Experimental Neurology, 2018, vol. 77, num. 7, p. 577-597</dc:relation>
   <dc:rights>(c) American Association of Neuropathologists, 2018</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>American Association of Neuropathologists</dc:publisher>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>